Loading...
Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone
BACKGROUND: The optimal sequence of the multiple active agents now available for metastatic castration-resistant prostate cancer (mCRPC) is unclear. Prior reports have suggested diminished responses to sequential lines of androgen receptor (AR)-targeted therapies, but it is unknown whether subsequen...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2014
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4144818/ https://ncbi.nlm.nih.gov/pubmed/25053178 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.22844 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|